Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Schizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, n...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of Inflammation 2016-01, Vol.2016 (2016), p.1044-1051-094
Main Authors: Gambi, Francesco, Martinotti, Giovanni, di Giannantonio, Massimo, Carano, Alessandro, Girinelli, Gabriella, Valchera, Alessandro, Orsolini, Laura, Santacroce, Rita, Vellante, Federica, De Berardis, Domenico, Marini, Stefano, Fornaro, Michele
Format: Article
Language:English
Subjects:
Angiogenesis inhibitors
Animal cognition
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Brain research
Celecoxib
Celecoxib - therapeutic use
Chronic illnesses
Clinical trials
Cytokines
Database searching
Dopamine
Drug therapy
Humans
Hypotheses
Inflammation
Internet/Web search services
Online searching
Psychopathology
Psychotropic drugs
Randomized Controlled Trials as Topic
Review
Schizophrenia
Schizophrenia - drug therapy
Studies
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Schizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, numerous immune modulation and anti-inflammatory treatment options have been proposed for schizophrenia, but sometimes the results were inconsistent. Electronic search was carried out in November 2015. PubMed and Scopus databases have been used to find studies to introduce in this review. Only randomized-placebo-controlled add-on trials were taken into account. In this way, six articles were obtained for the discussion. Celecoxib showed beneficial effects mostly in early stages of schizophrenia. In chronic schizophrenia, the data are controversial, possibly in part for methodological reasons.
ISSN:0962-9351
1466-1861
DOI:10.1155/2016/3476240